<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of actinic keratosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of actinic keratosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of actinic keratosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brian Berman, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert P Dellavalle, MD, PhD, MSPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            June K Robinson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 23, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Actinic keratoses (AKs), or solar keratoses, are keratotic or scaling macules, papules, or plaques resulting from the intraepidermal proliferation of atypical keratinocytes in response to prolonged exposure to ultraviolet radiation. Although most AKs do not progress to squamous cell carcinoma (SCC), AKs are a concern because the majority of cutaneous squamous cell carcinomas (cSCCs) arise from pre-existing AKs, and AKs that will progress to SCC cannot be distinguished from AKs that will spontaneously resolve or persist [
         <a href="#rid1">
          1,2
         </a>
         ]. Because of these factors, most clinicians routinely treat AKs [
         <a href="#rid3">
          3
         </a>
         ]. Improvement in associated symptoms and cosmetic appearance can be additional benefits of treatment.
        </p>
        <p>
         The treatment of AKs will be reviewed here. The epidemiology, clinical manifestations, and diagnosis of AKs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13712.html" rel="external">
          "Actinic keratosis: Epidemiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1686938524">
         <span class="h1">
          CHOICE OF THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are multiple effective treatment options for actinic keratosis (AK), including destructive therapies (eg, cryosurgery, surgery, dermabrasion, photodynamic therapy [PDT]), topical medications (eg, topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         , topical
         <a class="drug drug_general" data-topicid="130360" href="/z/d/drug information/130360.html" rel="external">
          tirbanibulin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">
          diclofenac
         </a>
         ), and field ablation treatments (eg, chemical peels, laser resurfacing). The choice of therapy is influenced by several factors, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Number and distribution of lesions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lesion characteristics
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient preference (eg, office-based versus home-administered therapy, duration of therapy)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient tolerance for side effects (eg, pain, inflammation, hypopigmentation, scarring)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment availability and cost
        </p>
        <p>
        </p>
        <p>
         Our approach is based on the above considerations and is consistent with current international and national guidelines  (
         <a class="graphic graphic_algorithm graphicRef121292" href="/z/d/graphic/121292.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid4">
          4-8
         </a>
         ]. In general, lesion-directed treatments, such as cryosurgery and surgical procedures, are the primary approach for isolated lesions [
         <a href="#rid3">
          3
         </a>
         ]. Field-directed therapies, such as topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         ,
         <a class="drug drug_general" data-topicid="130360" href="/z/d/drug information/130360.html" rel="external">
          tirbanibulin
         </a>
         , and PDT, are particularly useful for treating areas with multiple AKs.
        </p>
        <p class="headingAnchor" id="H2494524657">
         <span class="h1">
          ONE OR FEW DISCRETE LESIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2469156364">
         <span class="h2">
          Liquid nitrogen cryosurgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest liquid nitrogen cryosurgery as first-line therapy for patients with one or a few (two to three or more, depending on the patient's tolerance of treatment) isolated actinic keratoses (AKs)  (
         <a class="graphic graphic_algorithm graphicRef121292" href="/z/d/graphic/121292.html" rel="external">
          algorithm 1
         </a>
         ). Cryosurgery can be quickly performed in an office-based setting, does not require local anesthesia, is inexpensive, is well tolerated by patients, and, in most cases, results in good or excellent cosmetic outcome [
         <a href="#rid9">
          9
         </a>
         ]. However, since this procedure does not produce a specimen for histologic confirmation, it should only be performed when the clinical diagnosis of AK is relatively certain. If there is doubt about the diagnosis, a biopsy for histologic confirmation is warranted.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – The treatment is delivered by either spray or contact with a cryoprobe. The contact technique is particularly useful for treating small lesions in sensitive areas of the face (eg, periocular, perioral). The freezing time varies from 5 to 10 seconds or more, depending upon lesion size and thickness, with the "ice ball" extending at least 1 mm beyond the clinical margin of the lesion. A single freeze-thaw cycle is adequate for thin lesions, while a double freeze-thaw cycle is required for thicker lesions [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/109151.html" rel="external">
          "Minor dermatologic procedures", section on 'Cryotherapy (cryosurgery)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         <strong>
          and contraindications
         </strong>
         – Cryosurgery is associated with transient discomfort. Localized edema and the formation of a serohemorrhagic blister develop 12 to 36 hours following the procedure. Healing can result in hypopigmentation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cryosurgery is contraindicated for lesions that need pathologic examination to exclude malignancy and in patients with cold urticaria or cryoglobulinemia. (See
         <a class="medical medical_review" href="/z/d/html/109151.html" rel="external">
          "Minor dermatologic procedures", section on 'Cryotherapy (cryosurgery)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The efficacy of liquid nitrogen cryosurgery has been evaluated in a limited number of randomized trials.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a 2019 systematic review of eight randomized trials of cryosurgery combined with other topical treatments (ie,
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         , topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="17140" href="/z/d/drug information/17140.html" rel="external">
          ingenol mebutate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">
          diclofenac
         </a>
         ) versus cryosurgery alone, the response rate for cryosurgery alone ranged from 39 to 76 percent compared with 73 to 89 percent for combination therapy [
         <a href="#rid11">
          11
         </a>
         ]. The included studies were heterogeneous and generally of low methodologic quality.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Similar clearance rates for cryosurgery, ranging from 40 to 88 percent at three to six months, were reported in randomized trials comparing cryosurgery with other treatment modalities [
         <a href="#rid12">
          12-19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The wide variability in the reported clearance rates may be related to differences across studies in cryosurgery administration, such as freeze time, number of freeze-thaw cycles, use of contact versus spray technique, and distance from the spray tip to the AK [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2930915705">
         <span class="h2">
          Other destructive therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Shave excision and curettage, with or without electrodesiccation, and laser ablation with carbon dioxide (CO
         <sub>
          2
         </sub>
         ) or erbium-doped yttrium aluminum garnet (Er:YAG) lasers can be used for the treatment of isolated, hyperkeratotic AK lesions. None of these therapies has been evaluated in clinical trials, and their use is based upon limited evidence from small, observational studies and clinical experience. (See
         <a class="local">
          'Hypertrophic/hyperkeratotic lesions'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H635532831">
         <span class="h1">
          HYPERTROPHIC/HYPERKERATOTIC LESIONS
         </span>
        </p>
        <p class="headingAnchor" id="H591895604">
         <span class="h2">
          Initial treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest liquid nitrogen cryosurgery as the initial treatment for hypertrophic or hyperkeratotic lesions  (
         <a class="graphic graphic_picture graphicRef63461" href="/z/d/graphic/63461.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef121292" href="/z/d/graphic/121292.html" rel="external">
          algorithm 1
         </a>
         ). Because thick lesions are more resistant to liquid nitrogen, freezing times &gt;10 seconds or repeat applications may be necessary. We typically use two freeze-thaw cycles of 10 to 20 seconds, allowing time for the lesion's peripheral rim to thaw. (See
         <a class="medical medical_review" href="/z/d/html/109151.html" rel="external">
          "Minor dermatologic procedures", section on 'Cryotherapy (cryosurgery)'
         </a>
         .)
        </p>
        <p>
         For thick lesions that do not respond to liquid nitrogen cryosurgery, shave removal followed by electrodesiccation or cryosurgery to ensure hemostasis may be used as alternative treatment modalities. Lesion specimens should be sent for histopathologic examination to exclude squamous cell carcinoma (SCC). Of note, tissue specimens obtained by shave excision are usually not adequate to determine whether a lesion is invasive or intraepidermal. (See
         <a class="local">
          'When to biopsy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1275444308">
         <span class="h2">
          When to biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A skin biopsy that samples both the epidermis and dermis (eg, deep shave, punch, or incisional biopsy) for histopathologic examination to exclude or confirm the presence of in situ or invasive SCC should be performed in the following circumstances [
         <a href="#rid22">
          22
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">
          "Skin biopsy techniques"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lesions that appear indurated (a finding that suggests the possibility of SCC)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Painful, ulcerated, or bleeding lesions
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperkeratotic or hypertrophic actinic keratoses (AKs) that failed to resolve after standard therapies or recurred rapidly (&lt;3 months)
        </p>
        <p>
        </p>
        <p>
         A low threshold for considering the possibility of SCC is particularly important in patients who are immunocompromised, since these patients are more likely to have biologically aggressive lesions.
        </p>
        <p class="headingAnchor" id="H198056403">
         <span class="h1">
          MULTIPLE THIN LESIONS/FIELD CANCERIZATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with actinic keratosis (AK) often present with multiple lesions and evidence of chronic actinic damage in adjacent areas. This presentation is commonly referred to as "field cancerization." Sun damage indicative of field cancerization is clinically identified by at least two of the following signs: telangiectasia, atrophy, dyspigmentation, and sand paper-like texture [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p>
         Patients with multiple AKs and clinical evidence of field cancerization have an increased risk of developing a cutaneous squamous cell carcinoma (cSCC). They are best treated with so-called "field-directed therapies," which include topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         , and photodynamic therapy (PDT), or field-directed treatment in combination with lesion-directed treatment (sequential treatment)  (
         <a class="graphic graphic_algorithm graphicRef121292" href="/z/d/graphic/121292.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4090715020">
         <span class="h2">
          First-line therapies
         </span>
        </p>
        <p class="headingAnchor" id="H745769568">
         <span class="h3">
          Topical fluorouracil
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with multiple
         <strong>
          thin
         </strong>
         lesions on the face or scalp, we suggest field treatment with topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         cream as a first-line therapy  (
         <a class="graphic graphic_algorithm graphicRef121292" href="/z/d/graphic/121292.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid8">
          8,26
         </a>
         ]. Patients with multiple AKs who also have hypertrophic or hyperkeratotic lesions  (
         <a class="graphic graphic_picture graphicRef63461" href="/z/d/graphic/63461.html" rel="external">
          picture 1
         </a>
         ) may benefit from the sequential use of lesion-directed and field-directed therapies. (See
         <a class="local">
          'Sequential therapies'
         </a>
         below.)
        </p>
        <p>
         Topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         is available in the United States as a 0.5%, 4%, or 5% cream and as a 2% solution; 1% cream is no longer available in the United States but may be available in other countries. We typically use 5% topical fluorouracil cream.
        </p>
        <p>
         Lower concentration preparations may be associated with better adherence to treatment because of a lower potential for local irritation [
         <a href="#rid27">
          27
         </a>
         ]. In Europe and Canada, a combination
         <a class="drug drug_general" data-topicid="111317" href="/z/d/drug information/111317.html" rel="external">
          fluorouracil-salicylic acid
         </a>
         topical solution (0.5%
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         in 10% salicylic acid) is also available.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          Fluorouracil
         </a>
         cream is applied once or twice daily for two to four weeks until superficial erosion occurs. Treatment courses of one, two, and four weeks have demonstrated superiority over placebo for the clearance of AKs, with the four-week course demonstrating the greatest benefit [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Applied to AK lesions,
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         cream causes inflammation and lesion necrosis  (
         <a class="graphic graphic_picture graphicRef76480" href="/z/d/graphic/76480.html" rel="external">
          picture 2
         </a>
         ). Inflammation typically subsides approximately two weeks after topical fluorouracil is discontinued. It typically takes four to six weeks (two to four weeks of which are active treatment) for the skin to progress through erythema, blistering, necrosis with erosion, and re-epithelialization. In patients with extensive AK, the treated area may become extremely inflamed. Thus, pretreatment patient information and education must be thorough to ensure adherence to treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Multiple randomized trials and meta-analyses have documented the efficacy of topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         alone or in combination with other topical agents for the treatment of AK [
         <a href="#rid4">
          4,29-31
         </a>
         ]. Treatment with topical fluorouracil may also be effective for the long-term control of AKs. (See
         <a class="local">
          'Long-term control and chemoprevention'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Topical
         </strong>
         <strong>
          fluorouracil
         </strong>
         <strong>
          5% as monotherapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A 2019 multicenter, randomized trial compared the efficacy of 5%
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         cream (twice daily for four weeks), 5%
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         cream (once daily, three times per week for four weeks),
         <a class="drug drug_general" data-topicid="16481" href="/z/d/drug information/16481.html" rel="external">
          methyl aminolevulinate
         </a>
         (MAL)-PDT, and 0.015%
         <a class="drug drug_general" data-topicid="17140" href="/z/d/drug information/17140.html" rel="external">
          ingenol mebutate
         </a>
         gel (once daily for three consecutive days) in 624 patients with AK lesions of any grade [
         <a href="#rid26">
          26
         </a>
         ]. At 12 months, the cumulative probability of treatment success (≥75 percent reduction in the number of AKs counted at baseline) for fluorouracil was 74.7 percent (95% CI 66.8-81.0). For imiquimod, MAL-PDT, and ingenol mebutate, these percentages were 53.9 percent (95% CI 45.4-61.6), 37.7 percent (95% CI 30.0-45.3), and 28.9 percent (95% CI 21.8-36.3), respectively. The rates of adverse events, including erythema, edema, erosions, blisters, scabbing, crusting, and pain, were similar in all treatment groups. A cost-effectiveness evaluation performed on data from this trial showed that topical fluorouracil treatment was more effective and less expensive compared with other therapies 12 months post-treatment [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A previous network meta-analysis evaluating the relative efficacy of PDT and several topical therapies for the outcome of "complete patient clearance" also concluded that topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         5% was the most effective treatment, followed (in order) by topical fluorouracil 0.5%,
         <a class="drug drug_general" data-topicid="9199" href="/z/d/drug information/9199.html" rel="external">
          aminolevulinic acid
         </a>
         (ALA)-PDT,
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         ,
         <a class="drug drug_general" data-topicid="17140" href="/z/d/drug information/17140.html" rel="external">
          ingenol mebutate
         </a>
         , MAL-PDT, cryosurgery, topical
         <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">
          diclofenac
         </a>
         , and placebo [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Topical
         </strong>
         <strong>
          fluorouracil
         </strong>
         <strong>
          0.5% in salicylic acid
         </strong>
         <strong>
          10%
         </strong>
         – In Europe and Canada, a combination
         <a class="drug drug_general" data-topicid="111317" href="/z/d/drug information/111317.html" rel="external">
          fluorouracil-salicylic acid
         </a>
         topical solution (0.5%
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         in 10% salicylic acid) is available for the treatment of slightly palpable or moderately thick, hyperkeratotic AK (grade I/II). The efficacy of this combination has been evaluated in a few randomized trials.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In one trial including 66 patients with an average of eight moderate to severe, hyperkeratotic AKs on the face or scalp, treatment with
         <a class="drug drug_general" data-topicid="111317" href="/z/d/drug information/111317.html" rel="external">
          fluorouracil-salicylic acid
         </a>
         topical solution (0.5%
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         in 10% salicylic acid) once daily for six weeks achieved a higher rate of histologic clearance than two cryosurgery treatments administered three weeks apart (62 versus 42 percent) [
         <a href="#rid16">
          16
         </a>
         ]. The recurrence rates of cleared lesions at 14 weeks were 39 percent in the fluorouracil-salicylic acid group and 85 percent in the cryosurgery group. Adverse events, including local erythema, scabbing, and crusting, were more common in the topical fluorouracil-salicylic acid group than in the cryosurgery group (24 versus 6 percent, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In another trial, 166 patients with a 25 cm
         <sup>
          2
         </sup>
         area of face or bald scalp with 4 to 10 clinically confirmed AK lesions were treated with
         <a class="drug drug_general" data-topicid="111317" href="/z/d/drug information/111317.html" rel="external">
          fluorouracil-salicylic acid
         </a>
         topical solution (0.5%
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         in 10% salicylic acid) or vehicle once daily for 12 weeks. Eight weeks after the end of treatment, more patients achieved complete clinical clearance in the active treatment group than in the vehicle group (69.5 versus 34.6 percent, respectively; odds ratio [OR] 4.9, 95% CI 2.3-10.5) [
         <a href="#rid33">
          33
         </a>
         ]. Adverse effects occurred more frequently in the fluorouracil-salicylic acid group than in the vehicle group and included erythema, pain, inflammation, scab, and erosion.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3146460044">
         <span class="h3">
          Topical fluorouracil plus calcipotriol
         </span>
         <span class="headingEndMark">
          —
         </span>
         The addition of
         <a class="drug drug_general" data-topicid="9181" href="/z/d/drug information/9181.html" rel="external">
          calcipotriol
         </a>
         (calcipotriene) 0.005% to topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         5% may
         <strong>
         </strong>
         enhance the efficacy of topical fluorouracil for the treatment of AKs by inducing thymic stromal lymphopoietin expression and influx of CD4+ T cells in the skin [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         In a small, randomized trial, 131 patients with 4 to 15 AKs within a 25 cm
         <sup>
          2
         </sup>
         area on the face, scalp, or upper extremities were treated with topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         5% plus
         <a class="drug drug_general" data-topicid="9181" href="/z/d/drug information/9181.html" rel="external">
          calcipotriol
         </a>
         ointment 0.005% or topical fluorouracil 5% plus vehicle twice daily for four days [
         <a href="#rid34">
          34
         </a>
         ]. At eight weeks, the mean reduction in the number of AKs in all treated areas was greater in patients treated with topical fluorouracil combined with calcipotriol than in patients treated with topical fluorouracil alone (88 versus 26 percent on the face, 76 versus 6 percent on the scalp, 69 versus 10 percent on the right upper extremity, and 79 versus 16 percent on the left upper extremity, respectively). Erythema and burning at the treated areas were more frequent in the combination treatment group than in the topical fluorouracil alone group.
        </p>
        <p class="headingAnchor" id="H3191165855">
         <span class="h3">
          Topical tirbanibulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical
         <a class="drug drug_general" data-topicid="130360" href="/z/d/drug information/130360.html" rel="external">
          tirbanibulin
         </a>
         , a synthetic inhibitor of tubulin polymerization and Src kinase signaling, is approved in the United States and Europe for field treatment of AK of the face and scalp [
         <a href="#rid35">
          35
         </a>
         ]. Cost considerations may limit availability in some formularies.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="130360" href="/z/d/drug information/130360.html" rel="external">
          Tirbanibulin
         </a>
         is applied once daily to up to a 25 cm
         <sup>
          2
         </sup>
         area for five consecutive days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Adverse events include pruritus, pain at the application site, erythema, vesiculation, superficial erosions, and desquamation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – In two identical, randomized, phase 3 trials, a 25 cm
         <sup>
          2
         </sup>
         contiguous area with four to eight AKs on the face or scalp of 702 adult patients was treated with either topical
         <a class="drug drug_general" data-topicid="130360" href="/z/d/drug information/130360.html" rel="external">
          tirbanibulin
         </a>
         1% ointment or vehicle (placebo) ointment once daily for five consecutive days [
         <a href="#rid36">
          36
         </a>
         ]. In the pooled data of the two trials, at day 57, complete clearance of AK in the treated areas occurred in 49 percent of patients in the tirbanibulin groups and in 9 percent of patients in the vehicle groups (difference, 41 percentage points; 95% CI 35-47). Local skin reactions (including erythema, flaking, or scaling) at the site of application in the two trials were mostly mild and resolved by day 29. Of the patients who had achieved clearance of all AKs in the treated area at day 57, 27 percent maintained complete clearance at one year.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Studies comparing the safety and long-term efficacy of
         <a class="drug drug_general" data-topicid="130360" href="/z/d/drug information/130360.html" rel="external">
          tirbanibulin
         </a>
         with those of other available agents for the field treatment of AK are lacking.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1989203002">
         <span class="h3">
          Imiquimod
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          Imiquimod
         </a>
         is a topical immune response modifier that can be used as an alternative to topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         for the treatment of multiple AKs and field cancerization, although its efficacy is inferior to that of topical fluorouracil. Imiquimod is available as a 5%, 2.5%, and 3.75% cream.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          Imiquimod
         </a>
         5% cream is typically applied to an involved area of ≤25 cm
         <sup>
          2
         </sup>
         twice weekly for 16 weeks. The cream is applied at night, ideally at least one hour before bedtime, and washed off after eight hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Preparations containing 2.5% and 3.75%
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         can be used for the treatment of the entire face
         <strong>
          or
         </strong>
         the entire scalp. These preparations are applied once daily for two, two-week cycles separated by two weeks of no treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          Imiquimod
         </a>
         stimulates local cytokine induction, resulting in a local, inflammatory reaction characterized by erythema, pruritus, erosion, ulceration, and crusting. Some patients may experience flu-like symptoms, such as fever, chills, myalgia, and malaise. The healing time of lesions treated with imiquimod is approximately two weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The efficacy of
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         for the treatment of AK has been evaluated in several randomized trials and meta-analyses [
         <a href="#rid26">
          26,29,31,37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A meta-analysis of five randomized trials including approximately 1300 patients found that treatment with
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         5% cream (two to three times per week for 12 to 16 weeks) resulted in complete resolution of AKs in 50 percent of patients compared with 5 percent with the control vehicle [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a 2014 network meta-analysis comparing the relative efficacy of several treatments for AK (including three different
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         regimens), the absolute complete clearance rate was 63 percent (95% CI 45.5-81.1) for imiquimod 5% for 16 weeks, 56 percent (95% CI 33.8-78.8) for imiquimod 5% for four weeks, and 40 percent (95% CI 15.6-64.2) for imiquimod 3.75% for four weeks [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a 2019 randomized trial comparing the efficacy of 5%
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         cream, 5%
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         cream (once daily, three times per week for four weeks), MAL-PDT, and 0.015%
         <a class="drug drug_general" data-topicid="17140" href="/z/d/drug information/17140.html" rel="external">
          ingenol mebutate
         </a>
         gel in 624 patients, treatment success at 12 months for imiquimod (defined as clearance of ≥75 percent of AKs counted at baseline) was 53.9 percent (95% CI 45.4-61.6), which was inferior to that of 5% topical fluorouracil (75 percent) [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2340647790">
         <span class="h3">
          Photodynamic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Photodynamic therapy (PDT) is an effective therapy for patients with multiple AKs, although it is not widely available in office-based dermatology practices  (
         <a class="graphic graphic_algorithm graphicRef121292" href="/z/d/graphic/121292.html" rel="external">
          algorithm 1
         </a>
         ). PDT consists of the topical application of a photosensitizer agent (ALA or MAL) to the involved area, followed by exposure to a visible wavelength light source. (See
         <a class="medical medical_review" href="/z/d/html/13647.html" rel="external">
          "Photodynamic therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3971768623">
         <span class="h4">
          Standard regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple PDT regimens have been used for the treatment of AK. Depending on the topical photosensitizer used, the incubation times, light sources, and pretreatment regimens have varied across studies, making it difficult to compare outcomes.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Photosensitizers and light sources
         </strong>
         – A 10% ALA gel is the only PDT product approved by the US Food and Drug Administration (FDA) for both lesion- and field-directed PDT that can be used with narrowband
         <strong>
          red
         </strong>
         light illumination [
         <a href="#rid39">
          39
         </a>
         ]. A 20% ALA solution is only used with
         <strong>
          blue
         </strong>
         light illuminators. However, the 10% ALA gel can also be used effectively and safely with blue light activation [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incubation time
         </strong>
         – The incubation time varies, depending on the photosensitizer formulation and the body site to be treated, and is usually determined by the treating clinician. As an example, the recommended incubation time is 3 hours for ALA gel and 14 to 18 hours for the ALA solution. An effect of the length of the incubation on treatment efficacy was illustrated in a randomized trial (n = 149) in which patients were treated with a self-adhesive ALA patch. The trial found that a four-hour incubation period was more effective for complete clearance of AKs than shorter incubation times of 30 minutes, 1 hour, or 2 hours [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The incubation time may affect the perceived pain intensity associated with the procedure. In an intrapatient-controlled, randomized trial designed to assess pain during the illumination phase of PDT, topical 20% ALA was applied to the entire face or scalp in 23 patients. Then, on one side, blue light was started immediately and continued for either 30, 45, or 60 minutes ("simultaneous PDT"), while on the contralateral side, blue light began one hour after ALA application and lasted 1000 seconds ("conventional PDT") [
         <a href="#rid42">
          42
         </a>
         ]. All patients experienced significantly less pain during simultaneous illumination than with conventional regimen, and at three months post-treatment, lesion clearance was nearly identical on the two sides (58 and 59 percent for simultaneous and conventional PDT, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Standard and modified PDT regimens for the treatment of AKs are described in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/13647.html" rel="external">
          "Photodynamic therapy", section on 'Standard photodynamic therapy regimens for actinic keratoses'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13647.html" rel="external">
          "Photodynamic therapy", section on 'Variations on the standard photodynamic therapy regimen'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Following PDT, a localized, erythematous reaction (similar to sunburn) can typically be expected for four to seven days and may be accompanied by a tingling or burning sensation, pain, edema, minute vesicles, or crusting. Skin exfoliation follows the inflammatory reaction for up to a week. The most common complaint during PDT is burning or stinging during light exposure; in addition, there is a small risk of producing pigmentary changes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Multiple trials and two meta-analyses have compared PDT with other therapies for AK [
         <a href="#rid12">
          12-15,29,43-46
         </a>
         ]. Although data are insufficient for definitive conclusions on comparative efficacy, the cosmetic outcome from
         <em>
         </em>
         PDT appears to be superior to topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         and cryosurgery [
         <a href="#rid29">
          29,46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One meta-analysis of four randomized trials (641 participants with 2170 AKs) comparing PDT with cryosurgery found that PDT had a 14 percent greater likelihood of achieving complete lesion clearance at three months than cryosurgery [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a multicenter, randomized trial (624 participants) evaluating the efficacy of topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         , PDT, and
         <a class="drug drug_general" data-topicid="17140" href="/z/d/drug information/17140.html" rel="external">
          ingenol mebutate
         </a>
         , the cumulative rate of treatment success (≥75 percent reduction in the number of AKs counted at baseline) at 12 months after last treatment was 37.7 percent (95% CI 30.0-45.3) for PDT, which was inferior to topical fluorouracil (75 percent) and imiquimod (54 percent) [
         <a href="#rid26">
          26
         </a>
         ]. All patients also underwent superficial curettage of their lesions prior to the topical field therapy, and patients could be retreated once if they did not achieve &gt;75 percent clearance of lesions from baseline.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2455670718">
         <span class="h4">
          Laser-assisted photodynamic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pretreatment of the involved area with ablative and nonablative laser devices appears to increase the efficacy of PDT [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         A meta-analysis of seven small, randomized, intraindividual trials found that laser-assisted PDT was associated with a higher likelihood of lesion clearance than PDT alone (89.5 versus 67.3 percent, respectively; relative risk 1.33, 95% CI 1.24-1.42), without a significant difference in the pain perceived by the patient [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H765573051">
         <span class="h4">
          Daylight photodynamic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Daylight photodynamic therapy (DLPDT) using topical MAL cream 16.8% (available in Europe and Canada but not in the United States) or ALA 10% gel is an alternative to conventional PDT for the treatment of patients with multiple AKs [
         <a href="#rid49">
          49,50
         </a>
         ]. Advantages of DLPDT include reduced to nearly absent pain, low cost, and ability to treat larger areas. (See
         <a class="medical medical_review" href="/z/d/html/13647.html" rel="external">
          "Photodynamic therapy", section on 'Daylight photodynamic therapy'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         DLPDT requires dry and warm weather conditions (outside temperature &gt;10°C [&gt;50°F]).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A high sun protection factor (SPF) broad-spectrum sunscreen that does
         <strong>
          not
         </strong>
         contain minerals (
         <a class="drug drug_general" data-topicid="10326" href="/z/d/drug information/10326.html" rel="external">
          zinc oxide
         </a>
         and titanium dioxide also filter visible light) is applied 15 minutes before the photosensitizing cream or emulsion.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thirty minutes after the application of the photosensitizer, patients are sent outside for two hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Multiple randomized trials and systematic reviews have shown that lesion clearance rates for DLPDT are similar to those seen with conventional PDT [
         <a href="#rid51">
          51-55
         </a>
         ]. In an intraindividual right-left comparison study, 46 patients with a total of 453 AKs were treated with DLPDT on one side of the face or scalp, followed by conventional PDT on the other side [
         <a href="#rid56">
          56
         </a>
         ]. Three months after treatment, the complete response rate was 78 percent for DLPDT versus 81 percent for conventional PDT. At 12 months, the response rate decreased to 72 and 74 percent for DLPDT and conventional PDT, respectively.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1337660890">
         <span class="h3">
          Other therapies
         </span>
        </p>
        <p class="headingAnchor" id="H3824764171">
         <span class="h4">
          Topical diclofenac
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical
         <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">
          diclofenac
         </a>
         3% in hyaluronan gel is a therapeutic option for AKs [
         <a href="#rid29">
          29,57,58
         </a>
         ]. Diclofenac is applied twice daily for 60 to 90 days. The most common adverse effects of diclofenac gel are dry skin, pruritus, erythema, and rash at the application site.
        </p>
        <p>
         The use of topical
         <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">
          diclofenac
         </a>
         is limited by its low efficacy compared with other topical treatments and its very long treatment course [
         <a href="#rid59">
          59,60
         </a>
         ]. A meta-analysis of three trials (364 patients) found that treatment with diclofenac gel resulted in complete resolution of AKs in approximately 40 percent of patients versus 12 percent with placebo [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2405483209">
         <span class="h4">
          Retinoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies suggest that topical retinoids (
         <a class="drug drug_general" data-topicid="9352" href="/z/d/drug information/9352.html" rel="external">
          adapalene
         </a>
         , tretinoin) used daily as field therapy have little or no efficacy in reducing the number of AKs [
         <a href="#rid62">
          62,63
         </a>
         ]. Low-dose oral
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         has shown some efficacy in reducing the number of AKs and preventing nonmelanoma skin cancer in organ transplant recipients [
         <a href="#rid64">
          64,65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3824603311">
         <span class="h4">
          Field ablation treatments
         </span>
        </p>
        <p class="headingAnchor" id="H2044793733">
         <span class="h5">
          Chemical peels
         </span>
         <span class="headingEndMark">
          —
         </span>
         A chemical peel is a procedure in which a topically applied wounding agent creates smooth, rejuvenated skin by way of a wound repair process, collagen remodeling, and exfoliation. (See
         <a class="medical medical_review" href="/z/d/html/13632.html" rel="external">
          "Chemical peels: Procedures and complications"
         </a>
         .)
        </p>
        <p>
         In a nonrandomized, split-face study, Jessner's solution plus 35%
         <a class="drug drug_general" data-topicid="10296" href="/z/d/drug information/10296.html" rel="external">
          trichloroacetic acid
         </a>
         (TCA) demonstrated similar efficacy and decreased rates of morbidity when compared with topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         , with a reduction of 75 percent in the number of visible AKs for both treatments [
         <a href="#rid66">
          66
         </a>
         ]. TCA 35% peel was compared with ALA-PDT for the treatment of AK in a split-area, randomized trial with 28 patients [
         <a href="#rid67">
          67
         </a>
         ]. At 12 months, complete clearance was noted for 49 percent of AKs treated with TCA compared with 74 percent of those treated with ALA-PDT.
        </p>
        <p class="headingAnchor" id="H3977082359">
         <span class="h5">
          Laser resurfacing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of ablative laser resurfacing with carbon dioxide (CO
         <sub>
          2
         </sub>
         ) and erbium-doped yttrium aluminum garnet (Er:YAG) lasers and nonablative fractional lasers for the treatment of AK has been reported in a few small, randomized trials and uncontrolled studies with variable results [
         <a href="#rid68">
          68-72
         </a>
         ]. In one study including 24 patients with facial photodamage and AKs treated with up to four treatments with a fractionated 1927 nm nonablative thulium laser, the number of AKs was reduced by 87 percent at six months [
         <a href="#rid68">
          68
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13629.html" rel="external">
          "Ablative laser resurfacing for skin rejuvenation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3350355010">
         <span class="h1">
          MULTIPLE LESIONS AND DISCRETE, HYPERTROPHIC LESIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1064382068">
         <span class="h2">
          Sequential therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with multiple thin actinic keratoses (AKs) who also have discrete, hyperkeratotic lesions may benefit from the sequential use of lesion-directed and field-directed therapies  (
         <a class="graphic graphic_algorithm graphicRef121292" href="/z/d/graphic/121292.html" rel="external">
          algorithm 1
         </a>
         ). For these patients, we suggest cryosurgery for the treatment of individual lesions followed by the application of
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         cream to the involved area.
        </p>
        <p>
         Examples of sequential treatments that have been evaluated in randomized trials include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cryosurgery before or after topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         [
         <a href="#rid73">
          73,74
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cryosurgery before or after topical
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         [
         <a href="#rid75">
          75
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Photodynamic therapy (PDT) before or after topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         [
         <a href="#rid76">
          76,77
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PDT before or after topical
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         [
         <a href="#rid78">
          78,79
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         The sequential use of lesion-directed therapies and field-directed therapies can optimize the clearance of visible, discrete lesions as well as subclinical lesions in photodamaged skin [
         <a href="#rid3">
          3,29,80,81
         </a>
         ]. A 2019 meta-analysis of 10 randomized trials (277 patients) evaluating PDT combined with topical therapies, including
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         , topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">
          tazarotene
         </a>
         , and
         <a class="drug drug_general" data-topicid="17140" href="/z/d/drug information/17140.html" rel="external">
          ingenol mebutate
         </a>
         , found that patients treated with combination therapy had a higher likelihood of complete clearance at the end of treatment (relative risk 1.63, 95% CI 1.15-2.33) [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         Applying a topical treatment after a lesion-directed approach may reduce the potential of subclinical lesions progressing to visible AKs. Conversely, pretreating areas of AK involvement with topical agents may reveal subclinical lesions that can be treated with destructive methods, such as cryosurgery.
        </p>
        <p class="headingAnchor" id="H1022983947">
         <span class="h1">
          SPECIAL BODY SITES
         </span>
        </p>
        <p class="headingAnchor" id="H1219551654">
         <span class="h2">
          Periocular area
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of topical agents (eg, topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         ) is generally avoided for the treatment of actinic keratoses (AKs) on the eyelids and periorbital area due to the high risk of conjunctival injury. Cautious cryosurgery, sometimes applied with a cotton swab, may be a safer approach.
        </p>
        <p class="headingAnchor" id="H3559106779">
         <span class="h2">
          Dorsal hands/forearms/legs
         </span>
         <span class="headingEndMark">
          —
         </span>
         AK lesions in these areas are generally thick and more treatment resistant. For AKs on the dorsum of the hands, cryosurgery followed by topical therapies (eg, topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         ) or photodynamic therapy (PDT) is often used [
         <a href="#rid83">
          83-85
         </a>
         ]. (See
         <a class="local">
          'Sequential therapies'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4223227901">
         <span class="h1">
          SOLID ORGAN TRANSPLANT RECIPIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Local destructive therapies, such as cryosurgery, curettage, or carbon dioxide (CO
         <sub>
          2
         </sub>
         ) laser, can be used for the management of individual actinic keratoses (AKs) in solid organ transplant recipients [
         <a href="#rid86">
          86
         </a>
         ]. Field-directed therapies, such as photodynamic therapy (PDT),
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         , and topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         , are often preferred options for patients with numerous lesions. Because these patients often have an inadequate response to therapy, repeated treatment is often necessary. Lesions that do not respond to multiple treatments should be excised and sent for histopathologic evaluation to exclude malignancy. (See
         <a class="medical medical_review" href="/z/d/html/16339.html" rel="external">
          "Prevention and management of skin cancer in solid organ transplant recipients"
         </a>
         .)
        </p>
        <p>
         Limited evidence from a small number of randomized trials favors the use of PDT over other treatment modalities in this patient population.
        </p>
        <p>
         A 2019 systematic review of eight small, randomized trials that included 242 solid organ transplant recipients found that
         <a class="drug drug_general" data-topicid="16481" href="/z/d/drug information/16481.html" rel="external">
          methyl aminolevulinate
         </a>
         (MAL)-PDT was generally associated with a higher clearance rate compared with
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         5% cream or topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         5% cream [
         <a href="#rid87">
          87
         </a>
         ]. The complete clearance rates at three to four months after the last treatment varied across studies, ranging from 40 to 76 percent for MAL-PDT and 28 to 62 percent for imiquimod. The studies were heterogeneous and generally of poor methodologic quality.
        </p>
        <p class="headingAnchor" id="H2790693312">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ongoing monitoring for lesion recurrence and cutaneous malignancies at 6 to 12 months post-treatment is required for all patients with a history of actinic keratoses (AKs). In a secondary analysis of a randomized trial that included 624 patients treated with 5%
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         , 5%
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         cream, methyl aminolevulinate-photodynamic therapy (MAL-PDT), or 0.015%
         <a class="drug drug_general" data-topicid="17140" href="/z/d/drug information/17140.html" rel="external">
          ingenol mebutate
         </a>
         gel, the total four-year risk of developing cutaneous squamous cell carcinoma (cSCC) in a previously treated area of AK was 3.7 percent (95% CI 2.4-5.7), varying from 2.2 percent (95% CI 0.7-6.6) in patients treated with fluorouracil to 5.8 percent (95% CI 2.9-11.3) in patients treated with imiquimod [
         <a href="#rid88">
          88
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/128194.html" rel="external">
          "Cutaneous squamous cell carcinoma: Primary and secondary prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3202061">
         <span class="h1">
          PREVENTION
         </span>
        </p>
        <p class="headingAnchor" id="H1109011319">
         <span class="h2">
          Sun protection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sun avoidance (especially during the peak hours in spring and summer), use of protective clothing, and regular use of broad-spectrum sunscreens are of key importance for the prevention of actinic keratoses (AKs). (See
         <a class="medical medical_review" href="/z/d/html/13751.html" rel="external">
          "Selection of sunscreen and sun-protective measures"
         </a>
         .)
        </p>
        <p>
         The efficacy of sunscreens in reducing the development of AKs has been demonstrated by several randomized trials [
         <a href="#rid89">
          89-91
         </a>
         ]. Daily sunscreen use may also decrease the risk of AK and squamous cell carcinoma (SCC) in immunosuppressed organ transplant recipients [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3073683269">
         <span class="h2">
          Long-term control and chemoprevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment with topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         or
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         may be effective for the long-term control of AKs and prevention of cutaneous squamous cell carcinoma (cSCC) [
         <a href="#rid93">
          93-95
         </a>
         ]. Chemoprevention of cSCC is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/128194.html" rel="external">
          "Cutaneous squamous cell carcinoma: Primary and secondary prevention", section on 'Chemoprevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4029414664">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/123054.html" rel="external">
          "Society guideline links: Actinic keratosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20605778">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/82940.html" rel="external">
          "Patient education: Actinic keratosis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of therapy
         </strong>
         – There are multiple effective treatment options for actinic keratosis (AK), including destructive therapies (eg, cryosurgery, surgery, dermabrasion, photodynamic therapy [PDT]), topical medications (eg, topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         , topical
         <a class="drug drug_general" data-topicid="130360" href="/z/d/drug information/130360.html" rel="external">
          tirbanibulin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">
          diclofenac
         </a>
         ), and field ablation treatments. The choice of therapy is influenced by several factors, including the number and distribution of lesions, patient preference and tolerance for side effects, and treatment availability and cost. Our approach to management is illustrated in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef121292" href="/z/d/graphic/121292.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Choice of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with one or few discrete, thin lesions
         </strong>
         – For patients with few isolated AKs, we suggest treatment with liquid nitrogen cryosurgery rather than other destructive treatments (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). A freezing time of 5 to 10 seconds is usually sufficient. Cryosurgery can be quickly performed in an office-based setting, is inexpensive, does not require local anesthesia, is generally well tolerated by patients, and, in most cases, results in good or excellent cosmetic outcome. (See
         <a class="local">
          'One or few discrete lesions'
         </a>
         above and
         <a class="local">
          'Hypertrophic/hyperkeratotic lesions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypertrophic/hyperkeratotic lesions
         </strong>
         – For hypertrophic or hyperkeratotic lesions  (
         <a class="graphic graphic_picture graphicRef63461" href="/z/d/graphic/63461.html" rel="external">
          picture 1
         </a>
         ), we suggest liquid nitrogen cryosurgery as the initial treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We typically use two freeze-thaw cycles of 10 to 20 seconds, allowing time for the lesion's peripheral rim to thaw. Shave removal followed by electrodesiccation or cryosurgery to ensure hemostasis may be used for suspicious lesions requiring histopathologic examination (eg, indurated lesions, painful or ulcerated lesions, lesions recurring in &lt;3 months). (See
         <a class="local">
          'Hypertrophic/hyperkeratotic lesions'
         </a>
         above and
         <a class="local">
          'When to biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multiple lesions/field cancerization
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Multiple thin lesions
         </strong>
         – For patients with multiple
         <strong>
          thin
         </strong>
         lesions on the face and/or scalp, we suggest field treatment with 5% topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         cream (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Alternative therapies include
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         ,
         <a class="drug drug_general" data-topicid="130360" href="/z/d/drug information/130360.html" rel="external">
          tirbanibulin
         </a>
         , or PDT. However, based on available data, these modalities appear to be less effective. (See
         <a class="local">
          'Multiple thin lesions/field cancerization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Multiple lesions including hypertrophic/hyperkeratotic lesions
         </strong>
         – Patients with multiple AKs who also have hypertrophic or hyperkeratotic lesions  (
         <a class="graphic graphic_picture graphicRef63461" href="/z/d/graphic/63461.html" rel="external">
          picture 1
         </a>
         ) may benefit from the sequential use of lesion-directed and field-directed therapies. For these patients, we suggest liquid nitrogen cryosurgery for the treatment of hyperkeratotic or hypertrophic lesions followed by the application of
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         cream on the involved area (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Sequential therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H120111561">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Joseph Jorizzo, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115:2523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; 1:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol 2013; 68:S28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. J Eur Acad Dermatol Venereol 2015; 29:2069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Berker D, McGregor JM, Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol 2017; 176:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poulin Y, Lynde CW, Barber K, et al. Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses. J Cutan Med Surg 2015; 19:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heppt MV, Leiter U, Steeb T, et al. S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. J Dtsch Dermatol Ges 2020; 18:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisen DB, Asgari MM, Bennett DD, et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol 2021; 85:e209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noels EC, Hollestein LM, van Egmond S, et al. Healthcare utilization and management of actinic keratosis in primary and secondary care: a complementary database analysis. Br J Dermatol 2019; 181:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arisi M, Guasco Pisani E, Calzavara-Pinton P, Zane C. Cryotherapy for Actinic Keratosis: Basic Principles and Literature Review. Clin Cosmet Investig Dermatol 2022; 15:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heppt MV, Steeb T, Ruzicka T, Berking C. Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol 2019; 180:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morton C, Campbell S, Gupta G, et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006; 155:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. J Am Acad Dermatol 2002; 47:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003; 14:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufmann R, Spelman L, Weightman W, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol 2008; 158:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon JC, Dominicus R, Karl L, et al. A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. J Eur Acad Dermatol Venereol 2015; 29:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foley P, Merlin K, Cumming S, et al. A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes. J Drugs Dermatol 2011; 10:1432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157 Suppl 2:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zane C, Facchinetti E, Rossi MT, et al. Cryotherapy is preferable to ablative CO2 laser for the treatment of isolated actinic keratoses of the face and scalp: a randomized clinical trial. Br J Dermatol 2014; 170:1114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol 2004; 43:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berman B, Shabbir AQ, MacNeil T, Knudsen KM. Variables in Cryosurgery Technique Associated With Clearance of Actinic Keratosis. Dermatol Surg 2017; 43:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dréno B, Amici JM, Basset-Seguin N, et al. Management of actinic keratosis: a practical report and treatment algorithm from AKTeam™ expert clinicians. J Eur Acad Dermatol Venereol 2014; 28:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figueras Nart I, Cerio R, Dirschka T, et al. Defining the actinic keratosis field: a literature review and discussion. J Eur Acad Dermatol Venereol 2018; 32:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dréno B, Cerio R, Dirschka T, et al. A Novel Actinic Keratosis Field Assessment Scale for Grading Actinic Keratosis Disease Severity. Acta Derm Venereol 2017; 97:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornejo CM, Jambusaria-Pahlajani A, Willenbrink TJ, et al. Field cancerization: Treatment. J Am Acad Dermatol 2020; 83:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jansen MHE, Kessels JPHM, Nelemans PJ, et al. Randomized Trial of Four Treatment Approaches for Actinic Keratosis. N Engl J Med 2019; 380:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yentzer B, Hick J, Williams L, et al. Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch Dermatol 2009; 145:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002; 70:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev 2012; 12:CD004415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta AK, Paquet M. Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol 2013; 169:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg 2005; 9:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jansen MHE, Kessels JPHM, Merks I, et al. A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands. Br J Dermatol 2020; 183:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stockfleth E, von Kiedrowski R, Dominicus R, et al. Efficacy and Safety of 5-Fluorouracil 0.5%/Salicylic Acid 10% in the Field-Directed Treatment of Actinic Keratosis: A Phase III, Randomized, Double-Blind, Vehicle-Controlled Trial. Dermatol Ther (Heidelb) 2017; 7:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunningham TJ, Tabacchi M, Eliane JP, et al. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest 2017; 127:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisen DB, Dellavalle RP, Frazer-Green L, et al. Focused update: Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol 2022; 87:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blauvelt A, Kempers S, Lain E, et al. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med 2021; 384:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006; 126:1251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vegter S, Tolley K. A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS One 2014; 9:e96829.
          </a>
         </li>
         <li class="breakAll">
          Ameluz [prescribing information]. Wakefield, MA: Biofrontera Inc.; 2016.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nestor MS, Berman B, Patel J, Lawson A. Safety and Efficacy of Aminolevulinic Acid 10% Topical Gel versus Aminolevulinic Acid 20% Topical Solution Followed by Blue-light Photodynamic Therapy for the Treatment of Actinic Keratosis on the Face and Scalp: A Randomized, Double-blind Study. J Clin Aesthet Dermatol 2019; 12:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hauschild A, Popp G, Stockfleth E, et al. Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. Exp Dermatol 2009; 18:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaw U, Ilyas M, Bullock T, et al. A regimen to minimize pain during blue light photodynamic therapy of actinic keratoses: Bilaterally controlled, randomized trial of simultaneous versus conventional illumination. J Am Acad Dermatol 2020; 82:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serra-Guillén C, Nagore E, Hueso L, et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol 2012; 66:e131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadley J, Tristani-Firouzi P, Hull C, et al. Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses. Dermatol Surg 2012; 38:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sotiriou E, Apalla Z, Maliamani F, et al. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. J Eur Acad Dermatol Venereol 2009; 23:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel G, Armstrong AW, Eisen DB. Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: a systematic review and meta-analysis. JAMA Dermatol 2014; 150:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labadie JG, Ibrahim SA, Worley B, et al. Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery. JAMA Dermatol 2022; 158:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steeb T, Schlager JG, Kohl C, et al. Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. J Am Acad Dermatol 2019; 80:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wulf HC. Photodynamic Therapy in Daylight for Actinic Keratoses. JAMA Dermatol 2016; 152:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dirschka T, Ekanayake-Bohlig S, Dominicus R, et al. A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis. J Eur Acad Dermatol Venereol 2019; 33:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubel DM, Spelman L, Murrell DF, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol 2014; 171:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacour JP, Ulrich C, Gilaberte Y, et al. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol 2015; 29:2342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao W, Guan M, Nong X, et al. The safety and efficacy of daylight photodynamic therapy in the treatment of actinic keratoses: a systematic review and meta-analysis. Int J Dermatol 2019; 58:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomás-Velázquez A, Redondo P. Switching From Conventional Photodynamic Therapy to Daylight Photodynamic Therapy For Actinic Keratoses: Systematic Review and Meta-analysis. Actas Dermosifiliogr 2017; 108:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mei X, Wang L, Zhang R, Zhong S. Daylight versus conventional photodynamic therapy for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials. Photodiagnosis Photodyn Ther 2019; 25:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sotiriou E, Evangelou G, Papadavid E, et al. Conventional vs. daylight photodynamic therapy for patients with actinic keratosis on face and scalp: 12-month follow-up results of a randomized, intra-individual comparative analysis. J Eur Acad Dermatol Venereol 2018; 32:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zane C, Facchinetti E, Rossi MT, et al. A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp. Br J Dermatol 2014; 170:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pflugfelder A, Welter AK, Leiter U, et al. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol 2012; 26:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pirard D, Vereecken P, Mélot C, Heenen M. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies. Arch Dermatol Res 2005; 297:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol 2003; 49:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstock MA, Bingham SF, VATTC Trial Group. High-dose topical tretinoin for reducing multiplicity of actinic keratoses (abstract). J Invest Dermatol 2010; 130 Suppl 1:S63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carneiro RV, Sotto MN, Azevedo LS, et al. Acitretin and skin cancer in kidney transplanted patients. Clinical and histological evaluation and immunohistochemical analysis of lymphocytes, natural killer cells and Langerhans' cells in sun exposed and sun protected skin. Clin Transplant 2005; 19:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadakia KC, Barton DL, Loprinzi CL, et al. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer 2012; 118:2128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995; 131:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holzer G, Pinkowicz A, Radakovic S, et al. Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolaevulinic acid photodynamic therapy for treating multiple actinic keratosis. Br J Dermatol 2017; 176:1155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss ET, Brauer JA, Anolik R, et al. 1927-nm fractional resurfacing of facial actinic keratoses: a promising new therapeutic option. J Am Acad Dermatol 2013; 68:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hantash BM, Stewart DB, Cooper ZA, et al. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol 2006; 142:976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostertag JU, Quaedvlieg PJ, van der Geer S, et al. A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses. Lasers Surg Med 2006; 38:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz TM, Goldberg LH, Marquez D, et al. Nonablative fractional photothermolysis for facial actinic keratoses: 6-month follow-up with histologic evaluation. J Am Acad Dermatol 2011; 65:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prens SP, de Vries K, Neumann HA, Prens EP. Non-ablative fractional resurfacing in combination with topical tretinoin cream as a field treatment modality for multiple actinic keratosis: a pilot study and a review of other field treatment modalities. J Dermatolog Treat 2013; 24:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jorizzo J, Weiss J, Furst K, et al. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol 2004; 140:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol 2006; 5:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan JK, Thomas DR, Poulin Y, et al. Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. J Cutan Med Surg 2007; 11:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanghetti EA, Hamann C, Tanghetti M. A Controlled Comparison Study of Topical Fluourouracil 5% Cream Pre-Treatment of Aminolevulinic Acid/Photodynamic Therapy for Actinic Keratosis. J Drugs Dermatol 2015; 14:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pei S, Kaminska ECN, Tsoukas MM. Treatment of Actinic Keratoses: A Randomized Split-Site Approach Comparison of Sequential 5-Fluorouracil and 5-Aminolevulinic Acid Photodynamic Therapy to 5-Aminolevulinic Acid Photodynamic Monotherapy. Dermatol Surg 2017; 43:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaffelburg M. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream. J Drugs Dermatol 2009; 8:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka N, Ohata C, Ishii N, et al. Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients. J Dermatol 2013; 40:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin GM. Impact of interval and combination therapies on the management of actinic keratosis: review and clinical considerations. J Dermatolog Treat 2011; 22:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stockfleth E. The paradigm shift in treating actinic keratosis: a comprehensive strategy. J Drugs Dermatol 2012; 11:1462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol 2019; 33:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hashim PW, Nia JK, Singer S, Goldenberg G. An Investigator-initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryosurgery in the Treatment of Hypertrophic Actinic Keratosis on Dorsal Hands. J Clin Aesthet Dermatol 2016; 9:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohl E, Popp C, Zeman F, et al. Photodynamic therapy using intense pulsed light for treating actinic keratoses and photoaged skin of the dorsal hands: a randomized placebo-controlled study. Br J Dermatol 2017; 176:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richard MA, Amici JM, Basset-Seguin N, et al. Management of actinic keratosis at specific body sites in patients at high risk of carcinoma lesions: expert consensus from the AKTeam™ of expert clinicians. J Eur Acad Dermatol Venereol 2018; 32:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ritchie SA, Patel MJ, Miller SJ. Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach. Dermatol Surg 2012; 38:1604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heppt MV, Steeb T, Niesert AC, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol 2019; 180:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmady S, Jansen MHE, Nelemans PJ, et al. Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatol 2022; 158:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naylor MF, Boyd A, Smith DW, et al. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol 1995; 131:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993; 329:1147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darlington S, Williams G, Neale R, et al. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol 2003; 139:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ulrich C, Jürgensen JS, Degen A, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161 Suppl 3:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pomerantz H, Hogan D, Eilers D, et al. Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. JAMA Dermatol 2015; 151:952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker JL, Siegel JA, Sachar M, et al. 5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial. J Invest Dermatol 2017; 137:1367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gollnick H, Dirschka T, Ostendorf R, et al. Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol 2020; 34:82.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5336 Version 53.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19382202" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2895318" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Malignant transformation of solar keratoses to squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23228304" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Current issues in the management of actinic keratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26370093" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28098380" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25926621" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32130773" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33820677" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Guidelines of care for the management of actinic keratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30636037" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Healthcare utilization and management of actinic keratosis in primary and secondary care: a complementary database analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35283641" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Cryotherapy for Actinic Keratosis: Basic Principles and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30447074" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17034536" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12140473" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12775317" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18341663" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25257941" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22134568" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18067630" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24472087" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cryotherapy is preferable to ablative CO2 laser for the treatment of isolated actinic keratoses of the face and scalp: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15357755" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A prospective study of the use of cryosurgery for the treatment of actinic keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28002105" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Variables in Cryosurgery Technique Associated With Clearance of Actinic Keratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24612407" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Management of actinic keratosis: a practical report and treatment algorithm from AKTeam™expert clinicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29055153" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Defining the actinic keratosis field: a literature review and discussion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28536731" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A Novel Actinic Keratosis Field Assessment Scale for Grading Actinic Keratosis Disease Severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32387663" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Field cancerization: Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30855743" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Randomized Trial of Four Treatment Approaches for Actinic Keratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19221274" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12353677" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23235610" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Interventions for actinic keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23550994" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16502198" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31961446" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27995485" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Efficacy and Safety of 5-Fluorouracil 0.5%/Salicylic Acid 10% in the Field-Directed Treatment of Actinic Keratosis: A Phase III, Randomized, Double-Blind, Vehicle-Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27869649" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35439607" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Focused update: Guidelines of care for the management of actinic keratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33567191" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16557235" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Imiquimod for actinic keratosis: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24892649" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24892649" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30988871" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Safety and Efficacy of Aminolevulinic Acid 10% Topical Gel versus Aminolevulinic Acid 20% Topical Solution Followed by Blue-light Photodynamic Therapy for the Treatment of Actinic Keratosis on the Face and Scalp: A Randomized, Double-blind Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18643849" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31525441" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A regimen to minimize pain during blue light photodynamic therapy of actinic keratoses: Bilaterally controlled, randomized trial of simultaneous versus conventional illumination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22226430" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22340282" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19470041" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25162181" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35976634" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30267719" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26843088" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Photodynamic Therapy in Daylight for Actinic Keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30022544" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24861492" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26435363" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30198107" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The safety and efficacy of daylight photodynamic therapy in the treatment of actinic keratoses: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28063524" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Switching From Conventional Photodynamic Therapy to Daylight Photodynamic Therapy For Actinic Keratoses: Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30412779" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Daylight versus conventional photodynamic therapy for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28972663" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Conventional vs. daylight photodynamic therapy for patients with actinic keratosis on face and scalp: 12-month follow-up results of a randomized, intra-individual comparative analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11841372" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11737438" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24506666" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21414035" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16235081" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12833014" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : High-dose topical tretinoin for reducing multiplicity of actinic keratoses (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15659144" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Acitretin and skin cancer in kidney transplanted patients. Clinical and histological evaluation and immunohistochemical analysis of lymphocytes, natural killer cells and Langerhans' cells in sun exposed and sun protected skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21882176" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7857114" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28012181" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolaevulinic acid photodynamic therapy for treating multiple actinic keratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23041112" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : 1927-nm fractional resurfacing of facial actinic keratoses: a promising new therapeutic option.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16924046" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Facial resurfacing for nonmelanoma skin cancer prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16912977" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21621294" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Nonablative fractional photothermolysis for facial actinic keratoses: 6-month follow-up with histologic evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22515664" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Non-ablative fractional resurfacing in combination with topical tretinoin cream as a field treatment modality for multiple actinic keratosis: a pilot study and a review of other field treatment modalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15262691" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16485881" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18042331" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26580872" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A Controlled Comparison Study of Topical Fluourouracil 5% Cream Pre-Treatment of Aminolevulinic Acid/Photodynamic Therapy for Actinic Keratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28562434" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Treatment of Actinic Keratoses: A Randomized Split-Site Approach Comparison of Sequential 5-Fluorouracil and 5-Aminolevulinic Acid Photodynamic Therapy to 5-Aminolevulinic Acid Photodynamic Monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19180894" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24147543" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20528483" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Impact of interval and combination therapies on the management of actinic keratosis: review and clinical considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23377517" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : The paradigm shift in treating actinic keratosis: a comprehensive strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30710390" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27672408" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : An Investigator-initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryosurgery in the Treatment of Hypertrophic Actinic Keratosis on Dorsal Hands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27518833" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Photodynamic therapy using intense pulsed light for treating actinic keratoses and photoaged skin of the dorsal hands: a randomized placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29235161" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Management of actinic keratosis at specific body sites in patients at high risk of carcinoma lesions: expert consensus from the AKTeam™of expert clinicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22646842" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30188570" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Local interventions for actinic keratosis in organ transplant recipients: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35475852" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7857113" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : High sun protection factor sunscreens in the suppression of actinic neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8377777" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Reduction of solar keratoses by regular sunscreen use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12707092" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19775361" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25950503" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28532759" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : 5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31407414" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
